Risk group and death from prostate cancer: Implications for active surveillance in men with favorable intermediate-risk prostate cancer

JAMA Oncology

Volumn 1, Issue 3, 2015, Pages 334-340

  Raldow, Ann C ^a   Zhang, Danjie ^b   Chen, Ming Hui ^b   Braccioforte, Michelle H ^c   Moran, Brian J ^c   D'Amico, Anthony V ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c Prostate Cancer Foundation of Chicago   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ADVERSE EFFECTS; AGED; BRACHYTHERAPY; CANCER GRADING; EPIDEMIOLOGY; HEALTH SURVEY; HUMAN; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; UNITED STATES; WATCHFUL WAITING;

ADENOCARCINOMA; AGED; BRACHYTHERAPY; CHICAGO; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; PATIENT SELECTION; POPULATION SURVEILLANCE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; WATCHFUL WAITING;

EID: 84965090758     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2014.284     Document Type: Article

References (38)

1. National Comprehensive Cancer Network. Prostate Cancer, Version 2.2014. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed January 13, 2015.
2. Thomsen FB, Brasso K, Klotz LH, Røder MA, Berg KD, Iversen P. Active surveillance for clinically localized prostate cancer: a systematic review. J Surg Oncol. 2014;109(8):830-835.
3. Ross AE, Loeb S, Landis P, et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol. 2010;28(17):2810-2816.
4. Wilt TJ, Brawer MK, Jones KM, et al; Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367(3):203-213.
5. Aizer AA, Chen M-H, Hattangadi J, D'Amico AV. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer. BJU Int. 2014;113(1):43-50.
6. Zumsteg ZS, Spratt DE, Pei I, et al. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol. 2013;64(6):895-902.
7. Keane FK, Chen MH, Zhang D, et al. The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease. Cancer. 2014;120(12):1787-1793.
8. Castle KO, Hoffman KE, Levy LB, et al. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era? Int J Radiat Oncol Biol Phys. 2013;85(3):693-699.
9. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL; ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29(9):1228-1242.
10. Albertsen PC. What is the risk posed by prostate cancer? J Natl Cancer Inst Monogr. 2012;2012(45):169-174.
11. Lane JA, Donovan JL, Davis M, et al; ProtecT study group. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. Lancet Oncol. 2014;15(10):1109-1118.
12. Klotz L. Active surveillance: the Canadian experience with an "inclusive approach". J Natl Cancer Inst Monogr. 2012;2012(45):234-241.
13. Klotz L, Vesprini D, Sethukavalan P, et al. Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer. J Clin Oncol. 2015;33(3):272-277.
14. Nanda A, Chen M-H, Braccioforte MH, Moran BJ, D'Amico AV. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA. 2009;302(8):866-873.
15. Hollander M, Wolfe D. Nonparametric Statistical Methods. New York, NY: John Wiley and Sons; 1999:106-140.
16. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
17. Agresti A. Categorical Data Analysis. New York, NY: John Wiley and Sons; 2013:69-112.
18. Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
19. Klein J, Moeschberger M. Survival Analysis Techniques for Censored and Truncated Data. New York, NY: Springer; 2003:295-328.
20. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29.
21. Hsieh FY, Lavori PW. Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Control Clin Trials. 2000;21(6):552-560.
22. Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. Biometrics. 1983;39(2):499-503.
23. Ankerst DP, Hoefler J, Bock S, et al. Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. Urology. 2014;83(6):1362-1367.
24. Russo AL, Chen M-H, Aizer AA, Hattangadi JA, D'Amico AV. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM). BJU Int. 2012;110(7):973-979.
25. Lee WR, deGuzman AF, Bare RL, Marshall MG, McCullough DL. Postimplant analysis of transperineal interstitial permanent prostate brachytherapy: evidence for a learning curve in the first year at a single institution. Int J Radiat Oncol Biol Phys. 2000;46(1):83-88.
26. Tamim H, Monfared AAT, LeLorier J. Application of lag-time into exposure definitions to control for protopathic bias. Pharmacoepidemiol Drug Saf. 2007;16(3):250-258.
27. Gaynor J, Feuer E, Tan C. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc. 1993;88:400-409.
28. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
29. Cupples LA, Gagnon DR, Ramaswamy R, D'Agostino RB. Age-adjusted survival curves with application in the Framingham Study. Stat Med. 1995;14(16):1731-1744.
30. Godtman RA, Holmberg E, Khatami A, Stranne J, Hugosson J. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial. Eur Urol. 2013;63(1):101-107.
31. Selvadurai ED, Singhera M, Thomas K, et al. Medium-term outcomes of active surveillance for localised prostate cancer. Eur Urol. 2013;64(6):981-987.
32. Dall'Era MA, Konety BR, Cowan JE, et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer. 2008;112(12):2664-2670.
33. Ercole B, Marietti SR, Fine J, Albertsen PC. Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era. J Urol. 2008;180(4):1336-1339.
34. Bul M, van den Bergh RC, Zhu X, et al. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int. 2012;110(11):1672-1677.
35. Thomsen FB, Røder MA, Hvarness H, Iversen P, Brasso K. Active surveillance can reduce overtreatment in patients with low-risk prostate cancer. Dan Med J. 2013;60(2):A4575.
36. Tosoian JJ, Trock BJ, Landis P, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol. 2011;29(16):2185-2190.
37. Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B, Manoharan M. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol. 2010;58(6):831-835.
38. Ischia JJ, Pang CY, Tay YK, Suen CF, Aw HC, Frydenberg M. Active surveillance for prostate cancer: an Australian experience. BJU Int. 2012;109(suppl 3):40-43.